NCT07864051Recruiting
Predicting Plaque Growth Using Blood Flow Stress Markers: A Proof-of-Concept Study
Plaque Prediction Obtained With Shear Stress Endothelial Metrics: A Proof of Principle Study
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Identifying plaques that are at higher risk of progression could help doctors provide earlier and more personalized treatment. The purpose of this study is to determine whether combining information about blood flow within the coronary arteries with information about a person's biological response to blood flow can improve prediction of plaque growth. Participants undergoing treatment for coronary artery disease will have a specialized heart scan to assess blood flow patterns around plaques in their coronary arteries. Researchers will also collect blood samples to study cells that line blood vessels and investigate how these cells respond to blood flow forces. The study will follow participants over time to determine whether plaques are more likely to progress in individuals who show a stronger biological response to abnormal blood flow. The findings may help researchers develop new ways to identify patients at higher risk of future heart problems and support the development of more personalized approaches to prevention and treatment of coronary artery disease.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 270 (estimated)
- First submitted
- 22 Sept 2026
- Start date
- 17 Sept 2026
- Primary completion date
- 1 Sept 2031
- Lead sponsor
- Queen Mary University of London
- Diseases
- Coronary artery disease
- NCT number
- NCT07864051
What you commit to
- Study type: Interventional
- Planned participants: 270
- From 17 Sept 2026 to the primary completion date, 1 Sept 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous coronary artery bypass surgery
- Patient allergic to contrast or cannot receive treatment with aspirin, heparin, or thienopyridines
- Patient that requires surgical revascularization
- Pregnant women will be excluded. All women of childbearing potential will undergo a pregnancy risk assessment and a urine pregnancy test prior to the 12-month PCCTA scan, in line with standard clinical practice for all PCCTA scans.
Other illness
- Acute coronary syndrome within \<3 months
- Flow limiting coronary artery disease in the proximal segments of all the 3 epicardial coronaries
- History of heart transplantation
- Extensive coronary artery disease (i.e., multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with intravascular imaging
Lab values
- Estimated glomerular filtration rate (eGFR) \<60ml/min/1.73m²
- Decompensated heart failure, or left ventricular ejection fraction ≤30%
Age
- Anticipated life expectancy \<2 years
Who the study is looking for
- Age ≥40
- Stable angina, defined as typical symptoms with evidence of reversible ischemia in non-invasive test and/or documented obstructive coronary artery disease on coronary angiography (\>70% stenosis of at least one major epicardial coronary artery or positive fractional flow reserve study)
- Patient that is willing and can provide written informed consent.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Queen Marys University London Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.